After @ year , we noted @ acute exacerbations in @ patients in the N-acetylcysteine group who received at least one dose and had at least one assessment visit ( @ exacerbations per patient-year ) and @ acute exacerbations in @ patients in the placebo group ( @ exacerbations per patient-year ; risk ratio @ , @ % CI @-@ ; p = @ ) .